Importance of identifying the early emergence of metastatic disease in prostate cancer
August 29th 2017In this Urology Times educational supplement, we review the importance of understanding the CRPC–mCRPC transition in order to optimize standard screening procedures and identify patients with early metastatic disease who may benefit from therapeutic intervention.
Genomic research may explain resistance to immunotherapy
August 18th 2017New research characterizing the molecular mechanisms regulating immune cell infiltration into the luminal subtype of muscle-invasive bladder cancer may explain resistance to treatment with immune checkpoint blockade and suggest a target for improving therapeutic response.
How prostate cancer genetics will change front-line care
August 1st 2017In this interview, Leonard G. Gomella, MD, provides an update on prostate cancer genetics, discusses the recent Prostate Cancer International Consensus Conference, and outlines why urologists should conduct more extensive family histories of their prostate cancer patients.
QoL better with bladder Ca immunotherapy vs. chemo
August 1st 2017Patients treated with pembrolizumab (Keytruda) as second-line therapy for advanced urothelial carcinoma following platinum-based chemotherapy maintain better health-related quality of life than their counterparts receiving chemotherapy, according to results from the phase III KEYNOTE-045 trial presented at the American Society of Clinical Oncology annual meeting in Chicago.
Side effects of modern PCa treatments compared
August 1st 2017Despite technological advances in treatment for localized prostate cancer, men continue to experience clinically meaningful side effects that affect quality of life, according to an examination of data from a prospective population-based cohort study.
Proposed MIPS rule modifies 2018 requirements
August 1st 2017The proposed rule for MACRA and the Merit-based Incentive Payment System program was released June 21, 2017-- As expected, the program requiring the implementation of the new MIPS scoring system and incentives to move to alternative payment models will continue.